CN1204315A - 新颖的苯基脒衍生物,其制法及其作为医药组合物的用途 - Google Patents
新颖的苯基脒衍生物,其制法及其作为医药组合物的用途 Download PDFInfo
- Publication number
- CN1204315A CN1204315A CN96198959A CN96198959A CN1204315A CN 1204315 A CN1204315 A CN 1204315A CN 96198959 A CN96198959 A CN 96198959A CN 96198959 A CN96198959 A CN 96198959A CN 1204315 A CN1204315 A CN 1204315A
- Authority
- CN
- China
- Prior art keywords
- represent
- alkyl
- base
- representative
- necessity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明是有关新颖的苯基脒衍生物,其制备方法及其作为药物组合物的用途。根据本发明苯基脒相当于通式Ⅰ的化合物。
Description
本发明是有关新颖的苯基脒衍生物,其制备方法及其作为药物组合物的用途。根据本发明的苯基脒相当于通式I的化合物其中A代表X1-CmH2m-X2-,其中m为整数2、3、4、5或6或且X1代表O,NH或NCH3;X2代表O,NH,NCH3或X3代表-X1-CnH2n-,其中n为整数1或2;X4代表-Cn-H2n-X1-,其中n为整数1或2;R1代表C5-7-环烷基,Ar1,OAr1,CH2-Ar2;CR4R5Ar3,或C(CH3)2R6;R2代表H,C1-6-烷基,OH,卤素或O-(C1-6)-烷基;R3代表H,或C1-6-烷基;R4代表C1-4-烷基,CF3,CH2OH,COOH,或COO(C1-4)-烷基;R5代表H,C1-4-烷基或CF3且R4和R5也可共同形成C4-6-亚烷基;R6代表CH2OH,COOH,COO(C1-4)-烷基,CONR9R10,或CH2NR9R10;R7代表H,卤素,OH,C1-6-烷基或C1-6-烷氧基;R8代表H,卤素,OH,C1-6-烷基或C1-6-烷氧基;R9代表H,C1-6烷基,苯基,苯基-(C1-6-烷基),COR11,COOR11,CHO,CONH2,CONHR11, SO2-(C1-6-烷基),SO2-苯基,其中苯基环可经卤素,CF3,C1-4-烷基,OH或C1-4-烷氧基单取代或多取代;R10代表H,C1-6-烷基且R9与R10也可共同代表C4-6-亚烷基;R11代表C1-6-烷基,C5-7-环烷基,芳基,杂芳基,芳烷基或杂芳基-(C1 -6-烷基),其中芳基或杂芳基可经Cl,F,CF3,C1-4-烷基,OH或C1-4-烷氧基单取代或多取代;Ar1代表必要时单取代或多取代的芳基,但未取代的苯基或经卤素,C1-4-烷基或C1-4-烷氧基单取代的苯基除外;Ar2代表必要时单取代或多取代的芳基,但未取代的苯基除外;Ar3代表必要时单取代或多取代的芳基,但其限制条件为:R1不可代表由C1-4-亚烷基单位键结的未取代的苯基;必要时它可呈个别光学异构体,各对映体的混合物,或外消旋体,也可呈游离碱,或其与医药上可接受的酸形成相应的酸加成盐。根据通式I的优选化合物其中A代表X1-Cm-H2m-X2-,其中m为整数2,或且X1为O;X2为X3代表-X1-CnH2n-,其中n为整数1或2;X4代表-Cn-H2n-X1-,其中n为整数1或2;R1代表C5-7-环烷基,Ar1,OAr1,CH2-Ar2;CR4R5Ar3,或C(CH3)2R6;R2代表H,C1-6-烷基,OH,Cl,或O-(C1-6)-烷基;R3代表H,或C1-6-烷基;R4代表C1-4-烷基,CF3或CH2OH;R5代表H,C1-4-烷基,CF3或CH2OH且R4与R5也可共同形成C4-6-亚烷基;R6代表CH2OH,COOH,COO(C1-4)-烷基,CONR9R10,或CH2NR9R10;R7代表H,F,Cl,Br,OH,C1-6-烷基或C1-6-烷氧基;R8代表H,F,Cl,Br,OH,C1-6-烷基或C1-6-烷氧基;R9代表H或C1-6-烷基;R10代表H或C1-6-烷基且R9与R10也可共同代表C4-6-亚烷基;Ar1代表必要时可单取代或多取代的芳基,但未取代的苯基或经卤素,C1-4-烷基或C1-4-烷氧基单取代的苯基除外;Ar2代表必要时可单取代或多取代的芳基,但未取代的苯基除外;Ar3代表必要时可单取代或多取代的芳基,但其限制条件为:R1不可代表由C1-4-亚烷基单位键结的未取代的苯基;必要时它可呈个别的光学异构体,各对映体的混合物或外消旋体,及呈游离碱型或其与医药上可接受的酸形成相应的酸加成盐。特别优选的通式I化合物为其中A代表且X1为O;X3代表X1-CH2;X4代表CH2-X1;R1代表C5-7-环烷基,Ar1,OAr1,CH2-Ar2;CR4R5Ar3,或C(CH3)2R6;R2代表H,OH或O-(C1-6)-烷基;R3代表H;R4代表CH3,或CH2OH;R5代表H,CH3或CH2OH且R4与R5也可共同代表C4-6-亚烷基;R6代表CH2OH,COOH,COO(C1-4)-烷基,CONR9R10,或CH2NR9R10;R7代表H;R8代表H;R9代表H或C1-6-烷基;R10代表H或C1-6-烷基且R9与R10也可共同代表C4-6-亚烷基;Ar1代表一个必要时经羟基或羟基和C1-6-烷基单取代或多取代的芳基;Ar2代表必要时可经羟基或羟基和C1-6-烷基单取代或多取代的芳基;Ar3代表必要时可经羟基或羟基和C1-6-烷基单取代或多取代的芳基;
必要时它可呈个别光学异构体,各对映体的混合物或外消旋体,且可呈游离碱型或它和医药上可接受的酸形成相应的酸加成盐。
除非另有说明,否则所采用的一般定义如下:
C1-4-烷基、C1-6-烷基及C1-8-烷基通常分别代表含1到4或6或8个碳原子的支链或直链的烃基。必要时它可经一个或多个相同或不同的卤原子取代,优选是氟。作为实例的烃基如下:
甲基、乙基、丙基、1-甲基乙基(异丙基)、正丁基、1-甲基丙基、2-甲基丙基、1,1-二甲基乙基、戊基、1-甲基丁基、2-甲基丁基、3-甲基丁基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、己基、1-甲基戊基、2-甲基戊基、3-甲基戊基、4-甲基戊基、1,1-二甲基丁基、1,2-二甲基丁基、1,3-二甲基丁基、2,2-二甲基丁基、2,3-二甲基丁基、3,3-二甲基丁基、1-乙基丁基、2-乙基丁基、1,1,2-三甲基丙基、1,2,2-三甲基丙基、1-乙基-1-甲基丙基与1-乙基-2-甲基丙基。除非另有说明,优选的是含1至4个碳原子的低级烷基,如:甲基、乙基、丙基、异丙基、正丁基、1-甲基丙基、2-甲基丙基或1,1-二甲基乙基。
芳基通常代表含6至10个碳原子的芳香基,芳香基也可经一个或多个下列基团取代:低级烷基、三氟甲基、氰基、烷氧基、硝基、氨基和/或一个或多个卤原子,它们可以相同或不同的;优选的芳基必要时可以是经取代的苯基,优选的取代基为卤素(如:氟、氯或溴)及羟基。
芳烷基通常代表由亚烷基链键结的C7-14-芳基,其中芳香基可经一个或多个下列基团取代:低级烷基、烷氧基、硝基、氨基和/或一个或多个卤原子,它们可以相同或不同。优选的是其脂族部分含1至6个碳原子而芳香族部分含6个碳原子的芳烷基。
除非另有说明,优选的芳烷基是苄基、苯乙基和苯丙基或2-苯基-异丙基。
烷氧基通常代表由氧原子键结的直链或支链的C1-8-烷基。优选的是含1至3个碳原子的低碳烷氧基。尤其是甲氧基。
除非另有说明,氨基代表NH2官能基,必要时它可由一个或二个C1-8-烷基、芳基或芳烷基取代,它们可相同或不同。
烷氨基实例是:甲氨基、乙氨基、丙氨基、1-亚甲基-乙氨基、丁氨基、1-甲基丙氨基、2-甲基丙氨基或1,1-二甲基乙氨基。
二烷氨基是例如:二甲氨基、二乙氨基、二丙氨基、二丁氨基、二-(1-甲基乙基)氨基、二-(1-甲基丙基)氨基、二-2-甲基丙氨基、乙基甲氨基或甲基丙氨基。
环烷基通常代表含5至9个碳原子的饱和或未饱和的环状烃基,必要时它可由一个或多个相同或不同的卤原子取代,优选的是氟。优选的环状烃基是含3至6个碳原子。其实例是:环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环庚基、环庚烯基、环庚二烯基、环辛基、环辛烯基、环辛二烯基及环壬烯基。
上述定义范围内的杂芳基通常是含氧、硫和/或氮作为杂原子并和另一个芳香环稠合的5至6员环。优选的是含一个氧,一个硫和/或至多二个氮原子且必要时可苯并稠合的5员及6员的芳香环。
特别的杂环系实例包括:吖啶基、吖啶酮基、烷基吡啶基、蒽醌基、抗坏血酸基、氮杂甘菊环基、氮杂苯并蒽基、氮杂苯并蒽烯基、氮杂基、氮杂环嗪基(Azacyclazinyl)、氮杂吲哚基、氮杂并四苯基、氮杂萘基、氮杂异戊烯基(azaprenyl)、氮杂三亚苯基、氮杂基、连氮基吲哚基、连氮基吡咯基、苯并吖啶基、苯并氮杂基(Benzazapinyl)、苯并呋喃基、苯并二氮杂萘基、苯并吡喃酮基、苯并吡喃基、苯并吡喃酮基、苯并喹啉基、苯并喹嗪基、苯并噻庚烷基(benzothiepinyl)、苯并苯硫基、苯并异喹啉基、二吡啶基、丁内酰基、己丙氨酰基(Caprolactamyl)、咔唑基、咔啉基、儿茶酸基、色烯吡喃酮基、色酮吡喃基、香豆素基、香豆酮基(Cumaronyl)、十氢喹啉基、十氢喹啉酮基、二氮杂蒽基、二氮杂菲基、二苯并氮杂基、二苯并呋喃基、二苯并苯硫基、二亚铬酰基、二氢呋喃基、二氢异香豆素基、二氢异喹啉基、二氢吡喃基、二氢吡啶基、二氢吡啶酮基、二氢吡喃酮基、二氢硫代吡喃基、diprylenyl、dioxanthylenyl、庚内酰胺基、黄烷基、黄烷酮基、荧烷基、荧光素基、呋喃二酮基、呋喃并苯并二氢吡喃基(Furanochromanyl)、呋喃酮基、呋喃并喹啉基、呋喃基、糠基吡喃基(Furopyranyl)、糠基吡喃酮基、杂甘菊环基、六氢吡嗪并异喹啉基、氢呋喃基、氢呋喃酮基、氢吲哚基、氢吡喃基、氢吡啶基、氢吡咯基、氢喹啉基、氢硫代色烯基、氢苯硫基、indolizidinyl、中氮印基、吲哚酮基、靛红基、靛红原基、异苯并呋喃二酮基、异苯并呋喃基、异苯并二氢吡喃基、异荧酮基、异二氢吲哚基、异吲哚苯并氮杂基、异吲哚基、异喹啉基、异奎宁环基、丙氨酰基(Lactamyl)、内酯基、马来酰亚胺基、单氮杂苯并萘次甲基、萘基、萘咪唑并吡啶二酮基、萘吲哚嗪二酮基、萘并二氢吡喃基、萘并呋喃基、二氮杂萘基、氧杂环庚烷基(Oxepinyl)、羟吲哚基、氧环戊烯基(Oxolenyl)、全氢唑并吡啶基、全氢吲哚基、菲醌基、苯并呋喃酮异喹啉基、酞酰亚氨基、邻羧基苯乙酮酰基、哌啶基、哌啶酮基、脯氨酰基、枸橡酸哌嗪基(parazinyl)、吡喃并吖嗪基、吡喃并唑基(pyranoazolyl)、吡喃并吡喃二酮基、吡喃并吡啶基、吡喃并喹啉基、吡喃并吡嗪基、吡喃基、吡唑并吡啶基、吡啶亚硫酰基、吡啶并萘基、吡啶并吡啶基、吡啶基、吡啶并可啉基、吡啶并吲哚基、吡啶并吡啶基、吡啶并嘧啶基、吡啶并吡咯基、吡啶并喹啉基、吡喃酮基、吡咯并可啉基、吡咯烷基、吡咯嗪烷基(Pyrrolizidinyl)、吡咯嗪基、吡咯并二吖嗪基(Pyrrolodioazinyl)、吡咯酮基、吡咯并嘧啶基、吡咯并喹啉酮基、吡咯基、喹吖啶酮基、喹啉基、喹嗪烷基(chinolizidinyl)、喹嗪基、喹啉酮基(chinolonyl)、奎宁环基、若丹明基、螺香豆满基(spirocumaranyl)、琥珀酰亚氨基、四氢噻吩砜基、二氧噻吩烯基(sulpholenyl)、四氢呋喃基、四氢异喹啉基、四氢吡喃基、四氢吡啶基、四氢噻喃基、四氢苯硫基、四氢硫杂吡喃酮基(Tetrahydrothipyranonyl)、四氢硫杂吡喃基、季酮基、硫杂苯基(Thiaphenyl)、硫杂苯并二氢吡喃基、硫杂萘烷基、硫杂秦次甲基、硫杂吡喃基、硫杂吡喃酮基、硫杂唑并吡啶基、噻吩并吡啶基、噻吩并吡咯基、噻吩并苯硫基、噻庚烷基(thiepinyl)、硫代色烯基、硫代香豆素基、硫代吡喃基、三氮杂蒽基、三嗪并吲哚基、***并吡啶基、托烷基、呫吨基、呫吨酮基、9-羟基呫吨基、腺嘌呤基、四氧嘧啶基、咯嗪基、邻氨基苯甲酰基、氮杂苯并蒽烯基、氮杂苯并萘次甲基、氮杂并四苯基、氮杂苯噁嗪基、氮杂嘌呤基、连氮基、唑并连氮基、唑基(Azolyl)、丙二酰脲、苯并嗪基、苯并咪唑亚硫酰基、苯并咪唑酮基、苯并异噻唑基、苯并异噁唑基、苯并噌啉基、苯并二吖辛因基、苯并二氧戊环基、苯并间二氧杂环戊烯基、苯并哒嗪基、苯并硫杂氮杂基、苯并噻嗪基、苯并噻唑基、苯并噁嗪基、苯并噁唑啉酮基、苯并噁唑基、噌啉基、depsidinyl、二氮杂菲基、二氮杂基、二嗪基、二苯并氧杂氮杂基、二氢苯并咪唑基、二氢苯并噻嗪基、二氢噁唑基、二氢哒嗪基、二氢嘧啶基、二氢噻嗪基、二噁烷基、二氧杂环己烯基、二氧杂环庚烷基(Dioxepinyl)、二噁辛酮基(dioxinonly)、二氧戊环基(Dioxolanyl)、二氧杂环戊二烯酮基(Dioxolonyl)、二氧杂哌嗪基、二嘧啶并吡嗪基、二硫戊环基、二硫环戊烯基(Dithiolenyl)、二硫杂环戊二烯基(Dithiolyl)、黄素基、呋喃并嘧啶基、胍基醋酸内酰胺基(Glycocyamidinyl)、鸟嘌呤基、六氢吡嗪并异喹啉基、六氢哒嗪基、乙内酰脲基、氢咪唑基、氢枸橡酸哌嗪基(hydroparazinyl)、氢吡唑基、氢哒嗪基、氢嘧啶基、咪唑啉基、咪唑基、咪唑并喹唑啉基、咪唑并噻唑基、吲唑苯并吡唑基、indoxazenyl、肌苷基、异咯嗪基、异噻唑基、异噁唑烷基、异噁唑啉酮基、异噁唑啉基、异噁唑酮基、异噁唑基、2,4-二氧四氢蝶啶基(lumazinyl)、甲基胸腺碱酰基、甲基尿嘧啶基,吗啉基、萘咪唑基、乳清酰基、氧硫杂环己烷基、氧硫戊烷基、噁嗪酮基、噁唑烷酮基、噁唑烷基、噁唑烷酮基、噁唑啉酮基、噁唑啉基、噁唑酮基、噁唑并嘧啶基、噁唑基、全氢噌啉基、全氢吡咯并连氮基、全氢吡咯并噻嗪基、全氢噻嗪酮基、啶基、吩嗪基、吩噻嗪基、吩氧硫杂环己二烯基(phenoxathiinyl)、吩噁嗪基、吩噁嗪酮基、酞嗪基、哌嗪二酮基、哌嗪并二酮基、聚喹喔啉基、蝶啶基、蝶呤基、嘌呤基、吡嗪基、吡唑烷基、吡唑烷酮基、吡唑啉酮基、吡唑啉基(parazolinyl)、吡唑并苯并二氮杂基、吡唑酮基、吡唑并嘧啶基、吡唑并三嗪基、吡唑基、哒嗪基、哒嗪酮基、吡啶并吡嗪基、吡啶并嘧啶基、嘧啶亚硫酰基、嘧啶基、嘧啶二酮基、嘧啶并氮杂基、嘧啶并蝶啶基、吡咯并苯并二氮杂基、吡咯并二嗪基、吡咯并嘧啶基、喹唑烷基、喹唑啉酮基、喹唑啉基、喹噁啉基、磺内酰胺基、sultinyl、磺内酯基、四氢噁唑基、四氢吡嗪基、四氢哒嗪基、四氢喹喔啉基、四氢噻唑基、硫氮杂基、噻嗪基、噻唑烷酮基、噻唑烷基、噻唑啉酮基、噻唑啉基、噻唑并苯并咪唑基、噻唑基、噻吩并嘧啶基、噻唑烷酮基、胸腺嘧啶基、***并嘧啶基、尿嘧啶基、黄嘌呤基、木糖醇基、氮杂苯并萘次甲基、苯并糠噁烷酮基(Benzofuroxanyl)、苯并噻二嗪基、苯并三氮杂酮基、苯并***基、苯并噁二嗪基、二噁二嗪基、二噻哒唑基、二噻唑基、呋咱基、糠噁烷基、氢***基、羟三嗪基、噁二嗪基、噁二唑基、噁噻嗪酮基、噁***基、五嗪基、五唑基、petrazinyl、聚噁二唑基、斯德酮基(Sydonyl)、四噁烷基、四氮杂基、四嗪基、四唑基、噻二嗪基、噻二唑啉基、噻二唑基、噻二噁嗪基、噻三嗪基、噻***基、三氮杂基、三嗪并吲哚基、三嗪基、***啉二酮基、***啉基、***基、三噁烷基、三吩二噁噻嗪基、三吩二噻嗪基、三噻二氮杂基、三噻烷基或三氧戊烷基(Trioxolanyl)。
特别优选的杂芳基包括例如:噻吩基、呋喃基、吡啶基、嘧啶基、吡嗪基、哒嗪基、喹啉基、异喹啉基、喹唑基、喹噁啉基、噻唑基、苯并噻唑基、异噻唑基、噁唑基、苯并噁唑基、异噁唑基、咪唑基、苯并咪唑基、吡唑基及吲哚基。
该反应宜在有机溶剂中,于约0℃至反应混合物的沸点温度间进行,优选是在室温至约100℃或沸点(若该沸点较低时)之间。合适溶剂为极性溶剂如甲醇、乙醇与丙醇。
若起始物具有充分酸安定性时,则该反应可用相应的酸亚胺氯化物替代亚胺基酯进行。2)为了制备式I化合物,其中A由O或S键结下列至少一个环系:
反应:
(a)由式III苯酚或硫苯酚与式IV化合物反应式(III)中Z代表OH或SH,且R1、R2与R3如上述定义,式(IV)中A如上述定义,且L代表离核性脱离基;或(b)由式V苯酚或硫苯酚与式VI化合物反应式(V)中Z如上述定义,
式(VI)中A、R1、R2、R3及L如上述定义。
该反应是在非质子性溶剂如,二甲亚砜、二甲基甲酰胺、乙腈或醇类如甲醇、乙醇、或丙醇中,使用碱(金属碳酸盐、金属氢氧化物、金属氢化物),并在约0至140℃或反应混合物的沸点的温度间进行。
其中A和、R1至R3如上述定义。
还原偕胺肟的还原是催化性氢化作用,尤其是使用阮内镍,在低碳醇类如,甲醇中进行。
适当时,将式(VII)偕胺肟,在有计算量的作为终产物所需盐的特定酸的存在下溶于甲醇中,并于室温下,于微加压下,例如,5巴下进行氢化,直到停止吸收氢气为止。
起始物可由已知化合物按一般方法制得。
因此,方法1)的起始物可由相应的腈和HCl经由亚胺氯化物的步骤反应或直接和C1-6-醇类或苄基醇反应,在有酸如,HCl存在下反应而制得。也可将腈和H2S于溶剂如,吡啶或二甲基甲酰胺中,在有碱如,三乙胺的存在下反应,随后进行烷基化或苄基化作用,而产生式II化合物。
由相应于式II化合物的羧酸酰胺开始,与三烷基氧鎓盐如,三乙基氧鎓四氟硼酸盐。在溶剂如,二氯甲烷、四氢呋喃或二噁烷中,于0至50℃的温度之间,优选在室温下,进行反应,得到式II化合物。
为了制备通式VII化合物的起始物,可由相应的偕胺肟替代脒,类似于方法1)或2)进行反应,或类似于相应的腈进行反应,添加羟胺,可得到通式VII的起始物。
已发现式I化合物的特征在于其在医疗方面的多用性,可特别述及其中LTB4-受体拮抗剂性质所起作用的用途。这里特别指出:关节炎、气喘、慢性阻塞性肺部疾病,例如:慢性支气管炎、牛皮癣、溃疡性结肠炎、由非类固醇消炎药所引起的胃与肠部病变,囊纤维变性,早老性痴呆症、休克、再灌注伤害/缺血、动脉粥状硬化及多发性硬化。
该新颖化合物也可用于治疗或调节其中细胞由血液通过血管内皮细胞至组织内过程是重要的疾病或病症(例如:转移)或治疗或调节其中LTB4或另一种分子(如:12-HETE)和LTB4-受体的组合而影响细胞增殖(如:慢性骨髓性白血病)的疾病或病症。
该新颖化合物也可和其他活性物质组合使用,例如,用于相同病症的活性物质,或和抗过敏药、祛痰药(secretolylics)、β2-肾上腺素能药物,可吸入性使用的类固醇、抗组胺药和/或PAF-拮抗剂。它可局部、口服、经皮肤、经鼻、非经肠胃的或吸入投药。
其活性比可采用如WO 93/16036,15至17页所述的药理及生化试验法分析,该申请已作为本文的参考文献。
医疗或预防剂量不仅随各化合物的效力及患者的体重而定,而且也取决于待治疗病症的性质与严重性,经口服用量为10至500毫克之间,优选为20至250毫克。供吸入给药时,对患者的剂量在约0.5至25毫克活性物质之间,优选是约2至20毫克。
供吸入用的溶液通常含有约0.5至5%活性物质。该新颖化合物可呈一般制剂给药,例如:片剂、包衣片、胶囊、锭剂、粉剂、粒剂、液剂、乳液、糖浆、吸入用喷雾剂、软膏及栓剂。
下列实施例表示一些制剂的配方:配方实施例1.片剂组成本发明活性化合物 20重量份硬脂酸 6重量份葡萄糖 474重量份
依一般方式加工处理成份,形成重500毫克的片剂。若需要时,可增加或减少活性物质含量,且相应地减少或增加葡萄糖含量。2.栓剂组成本发明活性物质 100重量份乳糖粉末 45重量份可可奶油 1555重量份
依一般方式加工成份,形成重1.7克的栓剂。3.吸入用粉剂
取微粉化活性物质粉末(式I化合物;颗粒大小约0.5至7微米),的5毫克量填入硬明胶囊中,按需要添加微粉化乳糖。由一般吸入器中吸入粉末,例如,根据DE-A3345722,该申请作为本文的参考文献。合成实施例
偕胺肟:X=对-C(=NOH)NH2
取2.0克上式腈(X=对-CN)置入40毫升乙醇中,回流,滴加由1克Na2CO3的5毫升水溶液和1.24克羟胺×HCl的混合物。回流加热5小时后,蒸馏去除溶剂,残留物和50毫升水搅拌,以50毫升乙酸乙酯萃取3次,合并的有机相脱水。过滤后,真空蒸发至干,残留物经急骤色层法纯化(硅胶60,CH2Cl2/甲醇9∶1)。产物溶于乙醇中,以乙醇化的HCl溶液酸化,并使用醚沉淀析出盐酸盐,所得油与乙酸乙酯结晶。产量:2.0克白色晶体。
4-[[3-[[4-[1-(4-羟苯基)-1-甲基乙基]苯氧基]甲基]苯基]甲氧基]苯基羧亚氨酰胺盐酸盐(X=对-C(=NH)-NH2)
取2.0克上式偕胺肟(X=对-C(=NOH)-NH2)溶于50毫升甲醇中,使用5克经甲醇湿润的阮内镍,添加1毫升20%氯化铵溶液,在常压和室温下氢化5小时,抽吸过滤镍,溶液经硅藻土过滤,真空蒸发浓缩后,残留物和50毫升水搅拌。抽吸过滤晶体,并由乙醇/醚中再结晶2次。收率:1.0克脒化合物(上式,X=对-C(=NH)-NH2)的盐酸盐,溶点234-236℃。
惊人地发现,实施例及表中所示化合物具有优越的Ki值,其大多在0.2至0.7nmol/升的范围内(RB.LTB4/U937细胞)。
Claims (12)
1.通式I的化合物,必要时它呈个别的光学异构体,各对映体的混合物或消旋体,而且可呈游离碱或其和药物上可接受的酸形成相应的酸加成盐,其中A代表X1-CmH2m-X2-,其中,m为整数2、3、4、5或6或且X1代表O,NH或NCH3;X2代表O,NH,NCH3或X3代表-X1-CnH2n-,其中n为1或2;X4代表-Cn-H2n-X1-,其中n为1或2;R1代表C5-7-环烷基,Ar1,OAr1,CH2-Ar2;CR4R5Ar3,或C(CH3)2R6;R2代表H,C1-6-烷基,OH,卤素或O-(C1-6)-烷基;R3代表H,或C1-6-烷基;R4代表C1-4-烷基,CF3,CH2OH,COOH,或COO(C1-4)-烷基;R5代表H,C1-4-烷基或CF3且R4与R5也可共同形成C4-6-亚烷基;R6代表CH2OH,COOH,COO(C1-4)-烷基,CONR9R10,或CH2NR9R10;R7代表H,卤素,OH,C1-6-烷基或C1-6-烷氧基;R8代表H,卤素,OH,C1-6-烷基或C1-6-烷氧基;R9代表H,C1-6烷基,苯基,苯基-(C1-6-烷基),COR11,COOR11,CHO,CONH2,CONHR11,SO2-(C1-6-烷基),SO2-苯基,其中苯基环可被卤素,CF3,C1-4-烷基,OH或C1-4-烷氧基单取代或多取代;R10代表H,C1-6-烷基且R9与R10也可共同代表C4-6-亚烷基;R11代表C1-6-烷基,C5-7-环烷基,芳基,杂芳基,芳烷基或杂芳基-(C1-6-烷基),其中芳基或杂芳基可被Cl,F,CF3,C1-4-烷基,OH或C1-4-烷氧基单取代或多取代;Ar1代表必要时可单取代或多取代的芳基,但未取代的苯基或经卤素,C1-4-烷基或C1-4-烷氧基单取代的苯基除外;Ar2代表必要时单取代或多取代的芳基,但未取代的苯基除外;Ar3代表必要时单取代或多取代的芳基,但其限制条件为:R1不可代表由C1-4-亚烷基单位键结的未取代的苯基。
2.一种根据通式I的化合物,必要时它呈个别光学异构体,各对映体的混合物,或消旋体,而且可呈游离碱,或其和药物上可接受的酸形成相应的酸加成盐,其中A代表X1-Cm-H2m-X2-,其中m为整数2,或且X1为O;X2为X3代表-X1-CnH2n-,其中n为整数1或2;X4代表-CnH2n-X1-,其中n为整数1或2;R1代表C5-7-环烷基,Ar1,OAr1,CH2-Ar2;CR4R5Ar3,或C(CH3)2R6;R2代表H,C1-6-烷基,OH,Cl,或O-(C1-6)-烷基;R3代表H,或C1-6-烷基;R4代表C1-4-烷基,CF3或CH2OH;R5代表H,C1-4-烷基,CF3或CH2OH且R4与R5也可共同形成C4-6-亚烷基;R6代表CH2OH,COOH,COO(C1-4)-烷基,CONR9R10,或CH2NR9R10;R7代表H,F,Cl,Br,OH,C1-6-烷基或C1-6-烷氧基;R8代表H,F,Cl,Br,OH,C1-6-烷基或C1-6-烷氧基;R9代表H或C1-6-烷基;R10代表H或C1-6-烷基且R9与R10也可共同代表C4-6-亚烷基;Ar1代表必要时可单取代或多取代的芳基,但未取代的苯基和由卤素,C1-4-烷基单取代的苯基及由C1-4-烷氧基单取代的苯基除外;Ar2代表必要时可单取代或多取代的芳基,但未取代的苯基除外;Ar3代表必要时可单取代或多取代的芳基,但其限制条件为R1不代表由C1-4-亚烷基单位键结的未取代的苯基;
3.一种根据通式I的化合物,必要时它呈个别的光学异构体,各对映体的混合物或消旋体,并可呈游离碱型或其与药物上可接受的酸形成相应的酸加成盐,其中A代表且X1为O;X3代表X1-CH2;X4代表CH2-X1;R1代表C5-7-环烷基,Ar1,OAr1,CH2-Ar2;CR4R5Ar3,或C(CH3)2R6;R2代表H,OH或O-(C1-6)-烷基;R3代表H;R4代表CH3,或CH2OH;R5代表H,CH3或CH2OH且R4与R5也可共同代表C4-6-亚烷基;R6代表CH2OH,COOH,COO(C1-4)-烷基,CONR9R10或CH2NR9R10;R7代表H;R8代表H;R9代表H或C1-6-烷基;R10代表H或C1-6-烷基且R9与R10也可共同代表C4-6-亚烷基;Ar1代表必要时可由羟基或羟基和C1-6-烷基单取代或多取代的芳基;Ar2代表必要时可由羟基或羟基和C1-6-烷基单取代或多取代的芳基;Ar3代表必要时可由羟基或羟基和C1-6-烷基单取代或多取代的芳基。
5.根据权利要求4的方法,其特征在于,作为起始物可用相应的酸亚胺氯化物替代通式II的亚胺基酯。
8.根据通式I化合物的制备方法,其特征在于,还原式VII的偕胺肟其中A和R1至R3如权利要求1所定义,优选地是用催化方法,尤其是在有阮内镍存在下,在惰性极性溶剂,优选在低级醇,特别是在甲醇中,在提高的压力下,尤其是在5巴压力下进行。
9.一种药物制剂,它包含根据权利要求1至3中之一的化合物,或其酸加成盐,及常惯的助剂和载体。
10.根据权利要求1至3中之一的化合物作为药物的用途。
11.根据权利要求10的化合物作为具有LTB4-拮抗活性的药物的用途。
12.通式I化合物、其立体异构体及其酸加成盐在制备用于治疗关节炎、气喘、慢性阻塞性肺部疾病如:慢性支气管炎、牛皮癣、溃疡性结肠炎、因非类固醇消炎药引起的胃或肠的病变、囊纤维变性、早老性痴呆症、休克、再灌注伤害/缺血、动脉粥状硬化及多发性硬化中的药物的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19546452.4 | 1995-12-13 | ||
DE19546452A DE19546452A1 (de) | 1995-12-13 | 1995-12-13 | Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1204315A true CN1204315A (zh) | 1999-01-06 |
CN100366606C CN100366606C (zh) | 2008-02-06 |
Family
ID=7779950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB961989599A Expired - Fee Related CN100366606C (zh) | 1995-12-13 | 1996-12-11 | 苯基脒衍生物,其制法及其作为医药组合物的用途 |
Country Status (36)
Country | Link |
---|---|
US (1) | US6127423A (zh) |
EP (1) | EP1015421B1 (zh) |
JP (1) | JP4334016B2 (zh) |
KR (1) | KR100475207B1 (zh) |
CN (1) | CN100366606C (zh) |
AR (1) | AR005034A1 (zh) |
AT (1) | ATE263144T1 (zh) |
AU (1) | AU716473B2 (zh) |
BG (1) | BG64020B1 (zh) |
BR (1) | BR9611949A (zh) |
CO (1) | CO4750814A1 (zh) |
CZ (1) | CZ291860B6 (zh) |
DE (2) | DE19546452A1 (zh) |
DK (1) | DK1015421T3 (zh) |
EE (1) | EE04371B1 (zh) |
ES (1) | ES2218609T3 (zh) |
HK (1) | HK1016575A1 (zh) |
HR (1) | HRP960583B1 (zh) |
HU (1) | HUP9903733A3 (zh) |
IL (2) | IL123900A0 (zh) |
MX (1) | MX9803672A (zh) |
MY (1) | MY120683A (zh) |
NO (1) | NO311353B1 (zh) |
NZ (1) | NZ325235A (zh) |
PE (1) | PE23198A1 (zh) |
PL (1) | PL186720B1 (zh) |
PT (1) | PT1015421E (zh) |
RS (1) | RS49503B (zh) |
RU (1) | RU2184726C2 (zh) |
SI (1) | SI1015421T1 (zh) |
SK (1) | SK282212B6 (zh) |
TR (1) | TR199801039T2 (zh) |
TW (1) | TW438746B (zh) |
UA (1) | UA57013C2 (zh) |
WO (1) | WO1997021670A1 (zh) |
ZA (1) | ZA9610460B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110869362A (zh) * | 2017-05-12 | 2020-03-06 | 国立研究开发法人理化学研究所 | A类gpcr结合性化合物改性体 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19636689A1 (de) | 1996-09-10 | 1998-03-12 | Boehringer Ingelheim Kg | Neue Benzamidinderivate |
DE19637123A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Ingelheim Kg | Neue Pyranosidderivate |
ID24720A (id) | 1997-12-12 | 2000-08-03 | Novartis Ag | Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis |
US6635668B1 (en) * | 1998-07-22 | 2003-10-21 | The University Of North Carolina At Chapel Hill | Imidazoline receptor binding compounds |
EP1149069B1 (en) * | 1998-12-14 | 2004-08-25 | F. Hoffmann-La Roche Ag | Phenylglycine derivatives |
US6528491B2 (en) | 2000-10-24 | 2003-03-04 | Boehringer Ingelheim Pharma Kg | Pyranoside derivatives |
DE10052333A1 (de) * | 2000-10-24 | 2002-05-02 | Boehringer Ingelheim Pharma | Neue Sulfooxybenzamide |
US6489359B2 (en) | 2000-10-24 | 2002-12-03 | Boehringer Ingelheim Pharma Kg | Sulphoxybenzamides |
MXPA03006328A (es) * | 2001-01-16 | 2004-04-05 | Boehringer Ingelheim Pharma | Uso de antagonista de ltb4 para tratamiento y/o prevencion de enfermedades causadas por aumento de expresion de genes de mucina. |
PL368613A1 (en) * | 2001-07-14 | 2005-04-04 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Pharmaceutical formulation containing an ltb4 antagonist |
US20030119901A1 (en) * | 2001-07-14 | 2003-06-26 | Boehringer Ingelheim Pharma Kg | Pharmaceutical formulation containing an LTB4 antagonist |
US20040006092A1 (en) * | 2001-08-31 | 2004-01-08 | Neurochem, Inc. | Amidine derivatives for treating amyloidosis |
RS20050390A (en) * | 2002-11-26 | 2008-04-04 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg., | Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox 1/2 inhibitor |
US7262223B2 (en) * | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5246965A (en) * | 1991-06-11 | 1993-09-21 | Ciba-Geigy | Arylethers, their manufacture and methods of treatment |
EP0625138B1 (de) * | 1992-02-05 | 1999-06-02 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue amidinderivate, ihre herstellung und verwendung als arzneimittel mit ltb4-antagonistischer wirkung |
DE4309285A1 (de) * | 1993-03-23 | 1994-09-29 | Boehringer Ingelheim Kg | Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung |
DE4424714A1 (de) * | 1994-07-13 | 1996-01-18 | Boehringer Ingelheim Kg | Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff |
-
1995
- 1995-12-13 DE DE19546452A patent/DE19546452A1/de not_active Withdrawn
-
1996
- 1996-11-12 UA UA98073741A patent/UA57013C2/uk unknown
- 1996-11-18 TW TW085114139A patent/TW438746B/zh not_active IP Right Cessation
- 1996-11-27 PE PE1996000847A patent/PE23198A1/es not_active Application Discontinuation
- 1996-12-02 RS YU63696A patent/RS49503B/sr unknown
- 1996-12-11 WO PCT/EP1996/005529 patent/WO1997021670A1/de active IP Right Grant
- 1996-12-11 PT PT96943916T patent/PT1015421E/pt unknown
- 1996-12-11 JP JP52173497A patent/JP4334016B2/ja not_active Expired - Fee Related
- 1996-12-11 SK SK770-98A patent/SK282212B6/sk unknown
- 1996-12-11 TR TR1998/01039T patent/TR199801039T2/xx unknown
- 1996-12-11 DK DK96943916T patent/DK1015421T3/da active
- 1996-12-11 PL PL96327171A patent/PL186720B1/pl not_active IP Right Cessation
- 1996-12-11 HU HU9903733A patent/HUP9903733A3/hu unknown
- 1996-12-11 EP EP96943916A patent/EP1015421B1/de not_active Expired - Lifetime
- 1996-12-11 EE EE9800145A patent/EE04371B1/xx not_active IP Right Cessation
- 1996-12-11 BR BR9611949A patent/BR9611949A/pt not_active Application Discontinuation
- 1996-12-11 RU RU98112918/04A patent/RU2184726C2/ru not_active IP Right Cessation
- 1996-12-11 US US09/077,900 patent/US6127423A/en not_active Expired - Lifetime
- 1996-12-11 AR ARP960105608A patent/AR005034A1/es active IP Right Grant
- 1996-12-11 NZ NZ325235A patent/NZ325235A/xx unknown
- 1996-12-11 IL IL12390096A patent/IL123900A0/xx active IP Right Grant
- 1996-12-11 DE DE59610963T patent/DE59610963D1/de not_active Expired - Lifetime
- 1996-12-11 KR KR10-1998-0704412A patent/KR100475207B1/ko not_active IP Right Cessation
- 1996-12-11 AU AU13699/97A patent/AU716473B2/en not_active Ceased
- 1996-12-11 CN CNB961989599A patent/CN100366606C/zh not_active Expired - Fee Related
- 1996-12-11 SI SI9630673T patent/SI1015421T1/xx unknown
- 1996-12-11 CZ CZ19981836A patent/CZ291860B6/cs not_active IP Right Cessation
- 1996-12-11 ES ES96943916T patent/ES2218609T3/es not_active Expired - Lifetime
- 1996-12-11 AT AT96943916T patent/ATE263144T1/de active
- 1996-12-12 HR HR960583A patent/HRP960583B1/xx not_active IP Right Cessation
- 1996-12-12 CO CO96065302A patent/CO4750814A1/es unknown
- 1996-12-12 ZA ZA9610460A patent/ZA9610460B/xx unknown
- 1996-12-13 MY MYPI96005251A patent/MY120683A/en unknown
-
1998
- 1998-03-31 IL IL123900A patent/IL123900A/en not_active IP Right Cessation
- 1998-04-21 BG BG102395A patent/BG64020B1/bg unknown
- 1998-05-08 MX MX9803672A patent/MX9803672A/es not_active IP Right Cessation
- 1998-06-12 NO NO19982708A patent/NO311353B1/no unknown
-
1999
- 1999-04-19 HK HK99101677A patent/HK1016575A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110869362A (zh) * | 2017-05-12 | 2020-03-06 | 国立研究开发法人理化学研究所 | A类gpcr结合性化合物改性体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1204315A (zh) | 新颖的苯基脒衍生物,其制法及其作为医药组合物的用途 | |
EP1452524B1 (en) | "2-oxo-1-pyrrolidine derivative and its pharmaceutical uses" | |
FI78691C (fi) | Foerfarande foer framstaellning av i position 3-substituerade pyridazinderivat, vilka inverkar pao det centrala nervsystemet. | |
JPH08325263A (ja) | 新規2−アミノ−3−フェニルプロピオン酸誘導体 | |
CN1208409A (zh) | 新颖苄酰基胍衍生物,其制法及其在药物组合物制备中的用途 | |
JPH11508280A (ja) | 三環式アミノアルキルカルボキサミド;新規なドーパミンd▲下3▼受容体サブタイプに特異的なリガンド | |
KR900006118B1 (ko) | 4-퀴놀론 유도체의 제법 | |
HU194238B (en) | Process for preparing ortho-condensed pyrrole derivatives and pharmaceuticals comprising the same | |
JP2542218B2 (ja) | デカヒドロキノリンの新誘導体、それらの製造法及びそれらを含む薬剤 | |
CN115232126B (zh) | 一种β-卡波林-1,2,3-***化合物及其制备方法与抗阿尔兹海默病的应用 | |
AU2007315833A1 (en) | A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one | |
AU2004212328B2 (en) | Use of S-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | |
JPH01190632A (ja) | ベンゾチアゼピン誘導体の医薬への応用 | |
EP0851862B1 (en) | 1(hetero)aryl-4-(condensed thiazol-2-ylalkyl)-piperazine derivatives, their preparation and their use in the treatment of 5-ht1a-receptor mediated disorders | |
US6583138B1 (en) | Heterocyclic-ring condensed benzothiazine compound | |
JP2002080479A (ja) | 新規なベンゾチアジアジン化合物、その製造方法およびそれを含有する医薬組成物 | |
CN1342153A (zh) | 具有有利性质的苄酰基胍衍生物,其制法及其在制造药物中的用途 | |
CN115160341B (zh) | 苯并噁嗪类化合物及其药物用途 | |
KR100226328B1 (ko) | 4-(4-또는6-(트리플루오로메틸-2-피리디닐))-1-피페라지닐알킬치환된락탐 | |
CA2350560C (en) | Novel type condensed pyridazinone compounds | |
CN1205010A (zh) | 异噁唑烷衍生物 | |
JPH0291063A (ja) | 新規な6,11‐ジヒドロ‐ジベンゾ〔c,f〕〔1,2,5〕チアジアゼピン‐5,5‐ジオキシド誘導体,その塩及びその製造法 | |
AU662730B2 (en) | Neuroprotectant agents | |
JPH0211592A (ja) | 光学活性なジヒドロピリジンホスホン酸エステル | |
SU1060114A3 (ru) | Способ получени октагидро- @ -бензо-(4,5)-фуро-(3,2- @ )-изохинолинов или их солей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1016575 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080206 Termination date: 20100111 |